RxDoctor Payments Data

Bradley Cohen, DO

Neurology · Garden City, NYNPI 1558334961

Payments from drug & device makers

$21,248in general payments, 2019–2025

Across 1,213 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • SK Life Science, Inc.$2K
  • Biogen$1K
  • Genentech USA, Inc.$1K
  • UCB, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$941
  • plus $12K from 46 others

What the payments were for

  • Speaking & faculty fees$860%
  • Food & beverage$20,67197%
  • Education$4912%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$21,248 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$446,727
Medicare patients
288
Services billed
6,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate36$51,979
VraylarCariprazine Hcl23$33,697
XcopriCenobamate24$32,483
NamzaricMemantine Hcl/Donepezil Hcl40$31,774
RexultiBrexpiprazole14$19,573
TrintellixVortioxetine Hydrobromide18$11,678
Carbamazepine ErCarbamazepine36$7,308
Amitriptyline Hcl442$5,462
Memantine Hcl ErMemantine Hcl24$4,821
Gabapentin395$3,339
Carbidopa-Levodopa ErCarbidopa/Levodopa70$3,074
Escitalopram Oxalate313$2,210
Quetiapine Fumarate159$1,959
Donepezil Hcl216$1,518
Pregabalin72$1,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Namzaric$3,159$65,47163 claims
Sunovion Pharmaceuticals Inc.Aptiom$410$51,97936 claims
SK Life Science, Inc.Xcopri$1,691$32,48324 claims
Otsuka America Pharmaceutical, Inc.Rexulti$172$19,57314 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$717$11,67818 claims
Upsher-smith Laboratories LLCTopiramate$121$74291 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in Garden City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →